Skip to main content
Top
Published in: Medical Oncology 9/2017

Open Access 01-09-2017 | Original Paper

High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience

Authors: Iwona Filipczak-Bryniarska, Roger M. Krzyzewski, Jakub Kucharz, Anna Michalowska-Kaczmarczyk, Justyna Kleja, Jarosław Woron, Katarzyna Strzepek, Lucyna Kazior, Jerzy Wordliczek, Tomasz Grodzicki, Krzysztof Krzemieniecki

Published in: Medical Oncology | Issue 9/2017

Login to get access

Abstract

High-dose capsaicin patch is effective in treatment of neuropathic pain in HIV-associated neuropathy and diabetic neuropathy. There are no studies assessing effectiveness of high-dose capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy. We sought to determine the effectiveness of treatment of pain associated with chemotherapy-induced peripheral neuropathy with high-dose capsaicin patch. Our study group consisted of 18 patients with clinically confirmed oxaliplatin-induced neuropathy. Baseline characteristic including underling disease, received cumulative dose of neurotoxic agent, neuropathic symptoms, prior treatment and initial pain level were recorded. Pain was evaluated with Numeric Rating Scale prior to treatment with high-dose capsaicin and after 1.8 day and after 8 and 12 weeks after introducing treatment. Patients were divided into two groups accordingly to the amount of neurotoxic agent that caused neuropathy (high sensitivity and low sensitivity group). Most frequent symptoms of chemotherapy-induced neuropathy were: pain (88.89%), paresthesis (100%), sock and gloves sensation (100%) and hypoesthesis (100%). Initial pain level was 7.45 ± 1.14. Mean cumulative dose of oxaliplatin after which patients developed symptoms was 648.07 mg/m2. Mean pain level after 12 weeks of treatment was 0.20 ± 0.41. When examined according to high and low sensitivity to neurotoxic agent patients with low sensitivity had higher pain reduction, especially after 8 days after introducing treatment (69.55 ± 12.09 vs. 49.40 ± 20.34%; p = 0.02) and after 12 weeks (96.96 ± 5.56 vs. 83.93 ± 18.59%; p = 0.04). High-dose capsaicin patch is an effective treatment for pain associated with chemotherapy-induced neuropathy in patients treated with oxaliplatin. Patients with lower sensitivity to neurotoxic agents have better response to treatment and pain reduction.
Literature
1.
2.
go back to reference Mols F, Beijers T, Vreugdenhil G, et al. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22:2261–9.CrossRefPubMed Mols F, Beijers T, Vreugdenhil G, et al. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22:2261–9.CrossRefPubMed
3.
go back to reference Chu SH, Lee YJ, Lee ES. Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Support Care Cancer. 2015;23:513–24.CrossRefPubMed Chu SH, Lee YJ, Lee ES. Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Support Care Cancer. 2015;23:513–24.CrossRefPubMed
4.
go back to reference Padman S, Lee J, Kumar R, et al. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)–cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years. Support Care Cancer. 2015;23:861–9.CrossRefPubMed Padman S, Lee J, Kumar R, et al. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)–cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years. Support Care Cancer. 2015;23:861–9.CrossRefPubMed
5.
go back to reference Pachman DR, Watson JC, Lustberg MB, et al. Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2014;22:2281–95.CrossRefPubMed Pachman DR, Watson JC, Lustberg MB, et al. Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2014;22:2281–95.CrossRefPubMed
6.
go back to reference Yang YH, Lin JK, Chen WS, et al. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer. 2012;20:1491–7.CrossRefPubMed Yang YH, Lin JK, Chen WS, et al. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer. 2012;20:1491–7.CrossRefPubMed
7.
go back to reference Durand JP, Brezault C, Goldwasser F. Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs. 2003;14:423–5.CrossRefPubMed Durand JP, Brezault C, Goldwasser F. Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs. 2003;14:423–5.CrossRefPubMed
8.
go back to reference Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–8.CrossRefPubMed Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–8.CrossRefPubMed
9.
go back to reference Cartoni C, Brunetti GA, Federico V, et al. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. Support Care Cancer. 2012;20:2621–6.CrossRefPubMed Cartoni C, Brunetti GA, Federico V, et al. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. Support Care Cancer. 2012;20:2621–6.CrossRefPubMed
10.
go back to reference Fallon MT, Storey DJ, Krishan A, et al. Cancer treatment-related neuropathic pain: proof of concept study with menthol-a TRPM8 agonist. Support Care Cancer. 2015;23:2769–77.CrossRefPubMedPubMedCentral Fallon MT, Storey DJ, Krishan A, et al. Cancer treatment-related neuropathic pain: proof of concept study with menthol-a TRPM8 agonist. Support Care Cancer. 2015;23:2769–77.CrossRefPubMedPubMedCentral
11.
go back to reference Gewandter JS, Mohile SG, Heckler CE, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer. 2014;22:1807–14.CrossRefPubMedPubMedCentral Gewandter JS, Mohile SG, Heckler CE, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer. 2014;22:1807–14.CrossRefPubMedPubMedCentral
12.
go back to reference Wagner T, Poole C, Roth-Daniek A. The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis. Pain Med. 2013;14:1202–11.CrossRefPubMedPubMedCentral Wagner T, Poole C, Roth-Daniek A. The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis. Pain Med. 2013;14:1202–11.CrossRefPubMedPubMedCentral
13.
go back to reference Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a highconcentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106–12.CrossRefPubMed Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a highconcentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106–12.CrossRefPubMed
14.
go back to reference Simpson DM, Brown S, Tobias J, et al. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70:2305–13.CrossRefPubMed Simpson DM, Brown S, Tobias J, et al. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70:2305–13.CrossRefPubMed
15.
go back to reference Derry S, Sven-Rice A, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2013;28:2. Derry S, Sven-Rice A, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2013;28:2.
16.
go back to reference Mou J, Paillard F, Turnbull B, et al. Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. Pain. 2013;154:1632–9.CrossRefPubMed Mou J, Paillard F, Turnbull B, et al. Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. Pain. 2013;154:1632–9.CrossRefPubMed
17.
go back to reference Mou J, Paillard F, Turnbull B, et al. Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. Clin J Pain. 2014;30:286–94.CrossRefPubMed Mou J, Paillard F, Turnbull B, et al. Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. Clin J Pain. 2014;30:286–94.CrossRefPubMed
18.
go back to reference Katz NP, Mou J, Paillard FC, et al. Predictors of response in patients with postherpetic neuralgia and HIV-associated neuropathy treated with the 8% Capsaicin Patch (Qutenza). Clin J Pain. 2015;31:859–66.CrossRefPubMed Katz NP, Mou J, Paillard FC, et al. Predictors of response in patients with postherpetic neuralgia and HIV-associated neuropathy treated with the 8% Capsaicin Patch (Qutenza). Clin J Pain. 2015;31:859–66.CrossRefPubMed
19.
go back to reference Mainka T, Malewicz NM, Baron R, et al. Presence of hyperalgesia predicts analgesic efficacy of topically applied capsaicin 8% in patients with peripheral neuropathic pain. Eur J Pain. 2016;20:116–29.CrossRefPubMed Mainka T, Malewicz NM, Baron R, et al. Presence of hyperalgesia predicts analgesic efficacy of topically applied capsaicin 8% in patients with peripheral neuropathic pain. Eur J Pain. 2016;20:116–29.CrossRefPubMed
Metadata
Title
High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience
Authors
Iwona Filipczak-Bryniarska
Roger M. Krzyzewski
Jakub Kucharz
Anna Michalowska-Kaczmarczyk
Justyna Kleja
Jarosław Woron
Katarzyna Strzepek
Lucyna Kazior
Jerzy Wordliczek
Tomasz Grodzicki
Krzysztof Krzemieniecki
Publication date
01-09-2017
Publisher
Springer US
Published in
Medical Oncology / Issue 9/2017
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-017-1015-1

Other articles of this Issue 9/2017

Medical Oncology 9/2017 Go to the issue